These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 11724334

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.
    Giani C, Casalini P, Pupa SM, De Vecchi R, Ardini E, Colnaghi MI, Giordano A, Ménard S.
    Oncogene; 1998 Jul 30; 17(4):425-32. PubMed ID: 9696035
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
    Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Jun 30; 24(6):1369-83. PubMed ID: 15138577
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 10. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu.
    Hong RL, Spohn WH, Hung MC.
    Clin Cancer Res; 1999 Jul 01; 5(7):1884-91. PubMed ID: 10430096
    [Abstract] [Full Text] [Related]

  • 11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.
    Brysch W, Magal E, Louis JC, Kunst M, Klinger I, Schlingensiepen R, Schlingensiepen KH.
    Cancer Gene Ther; 1994 Jun 15; 1(2):99-105. PubMed ID: 7621247
    [Abstract] [Full Text] [Related]

  • 13. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
    Warrenfeltz SW, Lott SA, Palmer TM, Gray JC, Puett D.
    Mol Cancer Res; 2008 Nov 15; 6(11):1775-85. PubMed ID: 19010824
    [Abstract] [Full Text] [Related]

  • 14. Stable suppression of HER-2 gene expression using siRNA increases the lysis of human ovarian carcinoma cells mediated by NK-92 cell line.
    Zhou Y, Cheng Z, Zhu H, Feng D, Zhao W, Ling B, Wei H, Tian Z.
    Oncol Rep; 2008 Dec 15; 20(6):1425-31. PubMed ID: 19020724
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
    Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E, Reich MF, Shen R, Shi X, Tsou HR, Wang YF, Wissner A.
    Cancer Res; 2004 Jun 01; 64(11):3958-65. PubMed ID: 15173008
    [Abstract] [Full Text] [Related]

  • 16. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A.
    Oncol Rep; 2007 Feb 01; 17(2):465-9. PubMed ID: 17203189
    [Abstract] [Full Text] [Related]

  • 17. In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin.
    Nash MA, Loercher AE, Freedman RS.
    Cancer Res; 1999 Dec 15; 59(24):6192-6. PubMed ID: 10626812
    [Abstract] [Full Text] [Related]

  • 18. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
    Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM.
    Growth Regul; 1991 Jun 15; 1(2):72-82. PubMed ID: 1688187
    [Abstract] [Full Text] [Related]

  • 19. [Rhein lysinate induces apoptosis in breast cancer SK-Br-3 cells by inhibiting HER-2 signal pathway].
    Lin YJ, Huang YH, Zhen YZ, Liu XJ, Zhen YS.
    Yao Xue Xue Bao; 2008 Nov 15; 43(11):1099-105. PubMed ID: 19239027
    [Abstract] [Full Text] [Related]

  • 20. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
    Ramirez PT, Gershenson DM, Tortolero-Luna G, Ramondetta LM, Fightmaster D, Wharton JT, Wolf JK.
    Gynecol Oncol; 2001 Dec 15; 83(3):543-8. PubMed ID: 11733969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.